Register
Login:
Share:
Email Facebook Twitter

Early Stage Investment Opportunities: SyndicateRoom, investing from idea to IPO. Watch here

Share Views Episode 9 - Early Stage Investment Opportunities


Reneuron Share Price (RENE)



Share Price Information for Reneuron (RENE)


Share Price: 2.625Bid: 2.50Ask: 2.75Change: 0.00 (0.00%)No Movement on Reneuron
Spread: 0.25Spread as %: 10.00%Open: 2.625High: 2.625Low: 2.625Yesterday’s Close: 2.625

Reneuron Group Plc Ord 1P

Reneuron is listed in the FTSE AIM All-Share
Reneuron is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
2.625

Share Price SpacerBid
2.50

Share Price SpacerAsk
2.75

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
463,475

Share Price SpacerOpen
2.625

Share Price SpacerHigh
2.625

Share Price SpacerLow
2.625

Share Price SpacerClose
2.625

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 3,164.62m £83.07m 100,000

52 Week High 4.38 52 Week High Date 28-SEP-2015
52 Week Low 2.38 52 Week Low Date 11-JUL-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
14 250,193 213,282 -6.563 -0.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

23-Sep-16
15:35:49
2.70
36,594
Buy* 
2.50
2.75
988.04
Trade Type:
Ordinary

23-Sep-16
14:38:06
2.679
111,422
Buy* 
2.50
2.75
2,985
Trade Type:
Ordinary

23-Sep-16
14:22:14
2.66
37,784
Buy* 
2.50
2.75
1,005
Trade Type:
Ordinary




View more Reneuron trades >>

Directors Deals for Reneuron (RENE)
Trade DateActionNotifierPriceCurrencyAmountHolding
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Simon Christopher Cartmell held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Simon Christopher Cartmell
00787500
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Timothy (Tim) Corn held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Timothy (Tim) Corn
00200000
31-Mar-16Notification of Holding
Trade Notifier Information for ReNeuron Group
Christopher Evans held the position of Non-Executive Director at ReNeuron Group at the time of this trade.
 Christopher Evans
0024010525
View more Reneuron directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Fri 07:42Fredd1eboyPositive info c/of mol iii site2.625No Opinion
as we know recruitment now closed - clinical trial site updated 160916

http://clinicaltrials.gov/ct2/show/NCT02117635?term=reneuron&rank=2

looks like 23 actually recruited from original 21

Enrollment: 23
Study Start Date: June 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)

and a reminder what the original trial criterion was - this has subsequently been deleted in… Read More
Wed 19:48QuestionTimeDown but not out2.625No Opinion
Come on Rene let's have some positive info soon
18 Sep '16Fredd1eboyWednesday 21st Sept2.625No Opinion
Reminder.....

The Inaugural UK Regenerative Medicine Conference
20-21 September 2016

Royal Institute of British Architects, 66 Portland Place, London, W1B 1AD

14:50 Dr John Sinden
Reneuron
Short Presentation: Chronic disability after stroke: Can neural stem cells provide a cure?
13 Sep '16Fredd1eboyRE: Micheal Hunt involved in presentatn2.625No Opinion
Hi Sheer. As you say, a long way to go, but hopefully market appreciation of progress will be more evident towards year end and results for Ren001 pahases 1/2 results and Ren009. If we are really lucky we may get some update on Ren003.
Eitherway, the results have to be good. So heres hoping.
Freddie
13 Sep '16Fredd1eboyAbout time too....2.625No Opinion
If FDA actually does cracks down, it won't do us any harm. Probably a lot of good

http://www.pbs.org/newshour/rundown/fda-weighs-crackdown-shut-hundreds-stem-cell-clinics/#.V9Z7qBHalh0.twitter
13 Sep '16sheerRE: Micheal Hunt involved in presentatn2.625No Opinion
I hadn't heard it before so thank you - you are often an important source of news. Yes, for presumably a seasoned speaker his disfluencies were interesting as was his appearance as opposed to the CSO. I reflected on his decision not to emphasise our work with stroke victims and on the importance of us being on the same stage as GSK. It reinforced that we are at the beginning of a wider portfolio of commoditised therapies. but that we are still relatively small. The presentation reminded me… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Reneuron (RENE) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.